Cannabidiol Supplements in Romania: Bridging the Gap Between Marketed Claims and Clinical Reality DOI Creative Commons
Corina Andrei, George Mihai Nițulescu, Georgiana Nițulescu

et al.

Pharmacy, Journal Year: 2024, Volume and Issue: 12(6), P. 176 - 176

Published: Nov. 25, 2024

In recent years, the European market, including Romania, has witnessed a significant increase in promotion of cannabidiol (CBD)-based products, often presented as effective treatments for various health conditions. This study investigates inconsistencies between claims associated with these supplements and evidence from clinical trials. To identify products available on Romanian systematic review online pharmacies websites that specialize selling CBD-based been performed. Additionally, trials conducted to assess efficacy CBD specified indications. Our analysis revealed some claims, such those related post-traumatic stress disorder, lack substantial evidence. Moreover, even when support exists, dosages recommended are significantly lower than used trials, raising concerns about their efficacy. These findings highlight need stricter regulatory oversight more transparent communication ensure consumer expectations aligned scientific evidence, ultimately promoting informed decision-making safety.

Language: Английский

Insomnia in older adults: A review of treatment options DOI Open Access
Roberto León-Barriera, Margaret Chaplin, Jasleen Kaur

et al.

Cleveland Clinic Journal of Medicine, Journal Year: 2025, Volume and Issue: 92(1), P. 43 - 50

Published: Jan. 1, 2025

Insomnia is a common and challenging complaint in older adults (> 65 years) because of age-related alterations sleep physiology. Cognitive behavioral therapy for insomnia the gold standard treatment young as well patients. Both clinicians patients often prefer simplicity medication, but risks associated with some hypnotics increase age. Pharmacologic options include low-dose doxepin, melatonin, ramelteon, dual orexin receptor antagonists. A well-informed clinician can help navigate benefits both pharmacologic options.

Language: Английский

Citations

1
A randomised, placebo-controlled, double blind, crossover trial on the effect of a 20:1 cannabidiol: Δ9-tetrahydrocannabinol medical cannabis product on neurocognition, attention, and mood DOI Creative Commons
Brooke Manning, Amie C. Hayley, Sarah Catchlove

et al.

European Neuropsychopharmacology, Journal Year: 2024, Volume and Issue: 82, P. 35 - 43

Published: March 14, 2024

As cannabinoid-based medications gain popularity in the treatment of refractory medical conditions, it is crucial to examine neurocognitive effects commonly prescribed products ensure associated safety profiles. The present study aims investigate acute a standard 1 mL sublingual dose CannEpil®, medicinal cannabis oil containing 100 mg cannabidiol (CBD) and 5 Δ9-tetrahydrocannabinol (THC) on neurocognition, attention, mood. A randomised, double-blind, placebo-controlled, within-subjects design assessed 31 healthy participants (16 female, 15 male), aged between 21 58 years, over two-week experimental protocol. Neurocognitive performance outcomes were using Cambridge Neuropsychological Test Automated Battery, with Profile Mood States questionnaire, Bond-Lader Visual Analogue Scale used assess subjective state CannEpil increased Total Errors Spatial Span Correct Latency (median) Pattern Recognition Memory, while also increasing Efficiency Score (lower score indicates greater efficiency) relative placebo (all p < .05). Subjective Contentedness (p .01) Amicability .05) at around 2.5 h post dosing, placebo. Drowsiness or sedative effect was reported by 23 % three six hours administration. Plasma concentrations CBD, THC, their metabolites not significantly correlated any observed alterations state, adverse event occurrence. An impairs select aspects visuospatial working memory delayed pattern recognition, largely preserving mood states among individuals. Intermittent reports drowsiness sedation underscore inter-individual variability state. (ANZCTR; ACTRN12619000932167; https://www.anzctr.org.au)

Language: Английский

Citations

5
Cannabinoids for Treating Sleep DOI
Daniel Whibley, Tiffany J. Braley, Anna L. Kratz

et al.

Current Addiction Reports, Journal Year: 2025, Volume and Issue: 12(1)

Published: Feb. 19, 2025

Language: Английский

Citations

0
Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double‐Blind Placebo‐Controlled Crossover Pilot Trial DOI Creative Commons
Heather A. Hausenblas,

Stephanie Hooper,

Tarah Lynch

et al.

Health Science Reports, Journal Year: 2025, Volume and Issue: 8(2)

Published: Feb. 1, 2025

Conduct a pilot randomized double-blind placebo-controlled crossover trial for adults with subthreshold insomnia symptoms to examine the effectiveness of cannabinoids supplement on sleep quality and health outcomes. Adults (N = 20, Mage 47.40) were either Cannabinoids Supplement (CS) or Placebo Condition (PC) 10 days. The CS was an oral soft gel that contained 3 mg Δ9-tetrahydrocannabinol, 6 cannabinol, cannabidiol, 90 proprietary food-grade terpene blend. Following 2-week washout, they completed alternate condition. following validated questionnaires collected at baseline each condition: Insomnia Severity Index, Pittsburgh Sleep Quality Bergen Scale, Profile Mood States (POMS), Perceived Stress Pain Questionnaire. Trait Anxiety Inventory, Flinders Daytime Fatigue, Health-related Life Scale. Clinical registry number ISRCTN 15022302. When compared PC, had significantly improved quality/efficiency, symptoms, health-related life, p < 0.05. Nonsignificant improvements PC found POMS mood subscales tension, anger, fatigue, depression, vigor, as well anxiety. Esteem subscale from Baseline Post PC. Both Vigor baseline. CS. No adverse events reported. This cannabinoid-based formulation well-tolerated may improve adults' quality/efficiency life. Larger controlled trials are encouraged longer-term effects this in variety populations environments.

Language: Английский

Citations

0
Sleep and Substance Use: Exploring Reciprocal Impacts and Therapeutic Approaches DOI

Christopher Bolling,

M. Elizabeth Cardoni,

J. Todd Arnedt

et al.

Current Psychiatry Reports, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 25, 2025

Language: Английский

Citations

0
The differential effects of medicinal cannabis on mental health: A systematic review DOI
Nora de Bode, Emese Kroon, Sharon R. Sznitman

et al.

Clinical Psychology Review, Journal Year: 2025, Volume and Issue: unknown, P. 102581 - 102581

Published: March 1, 2025

Language: Английский

Citations

0
The effect of nightly use of 150 mg cannabidiol on daytime neurocognitive performance in primary insomnia: a randomized controlled pilot trial DOI Creative Commons
Andrea J. Narayan, Amie C. Hayley,

Sarah Rose

et al.

Psychopharmacology, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 17, 2024

Abstract Rationale Cannabidiol (CBD) is increasingly used as a sleep aid for insomnia; yet neurocognitive and subjective state effects following daily therapeutic use are unclear. Objectives To measure the effect of CBD on performance mood in population with primary insomnia. Methods This study randomized, placebo-controlled, parallel design incorporating single-blind placebo run-in week followed by two-week double-blind dosing period, during which participants consumed 150 mg ( N = 15) or sublingually 60-minutes before bed. Attention, executive function, reasoning, information processing, working episodic memory were assessed using CogPro system at beginning run-in, after 1-week 2-weeks dosing. Subjective states visual analogue scales side recorded daily. Results Cognitive was unaffected nightly supplementation (all p > 0.05). From baseline to trial conclusion, those receiving reported greater experience calmness, clear-headedness, coordination more likely report side-effects dry mouth relative < Conclusions Relative placebo, daytime cognitive functioning insomnia preserved under conditions. suggested an overall favourable safety profile, larger controlled trials thorough analyses varying phenotypes necessary corroborate these findings.

Language: Английский

Citations

1
Using Cannabis and CBD to Sleep: An Updated Review DOI
Isobel Lavender, Gill Garden, Ronald R. Grunstein

et al.

Current Psychiatry Reports, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 29, 2024

Language: Английский

Citations

1
A Cannabidiol/Terpene Formulation Increases Restorative Sleep in Insomniacs: A Double-Blind, Placebo-controlled, Randomized, Crossover Study DOI Open Access
Michael Wang,

Marcus Faust,

Scott Abbott

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown

Published: June 5, 2023

ABSTRACT Study Objectives Cannabidiol (CBD) is increasingly used as a health supplement, though few human studies have demonstrated benefits. The primary objective of this study was to evaluate the effects an oral CBD-terpene formulation on sleep physiology in insomniacs. Methods In double-blind, placebo-controlled, randomized clinical trial, 125 insomniacs received administration CBD (300 mg) and terpenes (1 mg each linalool, myrcene, phytol, limonene, α-terpinene, α-terpineol, α-pinene, β-caryophyllene) for ≥ four days/week over weeks using crossover design. medication devoid Δ 9 -Tetrahydrocannabinol (Δ -THC). outcome measure percentage time participants spent combination slow wave (SWS) rapid eye movement (REM) stages, measured by wrist-worn sleep-tracking device. Results This regimen significantly increased mean nightly SWS + REM compared placebo [mean (SEM), 1.28% (0.60%), 95% C.I. 0.09 2.46, P = 0.03]. More robust increases were observed with low baseline sleep, well day-sleepers. For select participants, increase averaged much 48 min/night four-week treatment period. had no effect total (TST), resting heart rate or variability, adverse events reported. Conclusions Select ratios may potential provide safe efficacious alternative over-the-counter (OTC) aids commonly prescribed medications. BRIEF SUMMARY Current Knowledge/Study Rationale Physicians are asked their patients regarding merits insomnia other ailments, but lack any rigorous research support recommending its use. current represents first placebo-controlled trial investigate how cannabidiol influences Impact contrast many OTC medicines, which critical immune system, tissue regeneration, cognition memory. These results, if confirmed larger trials, suggests that might offer promising prescription medications aids.

Language: Английский

Citations

1
Cannabidiol Supplements in Romania: Bridging the Gap Between Marketed Claims and Clinical Reality DOI Creative Commons
Corina Andrei, George Mihai Nițulescu, Georgiana Nițulescu

et al.

Pharmacy, Journal Year: 2024, Volume and Issue: 12(6), P. 176 - 176

Published: Nov. 25, 2024

In recent years, the European market, including Romania, has witnessed a significant increase in promotion of cannabidiol (CBD)-based products, often presented as effective treatments for various health conditions. This study investigates inconsistencies between claims associated with these supplements and evidence from clinical trials. To identify products available on Romanian systematic review online pharmacies websites that specialize selling CBD-based been performed. Additionally, trials conducted to assess efficacy CBD specified indications. Our analysis revealed some claims, such those related post-traumatic stress disorder, lack substantial evidence. Moreover, even when support exists, dosages recommended are significantly lower than used trials, raising concerns about their efficacy. These findings highlight need stricter regulatory oversight more transparent communication ensure consumer expectations aligned scientific evidence, ultimately promoting informed decision-making safety.

Language: Английский

Citations

0